We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other firms that ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best fundamentally strong penny stocks to buy according to ...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion ...

Recursion Pharmaceuticals, Inc. upgraded to Buy on promising REC-4881 data, strong partnerships, and AI-driven drug discovery ...

Based on the one-year price targets offered by 7 analysts, the average target price for Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is $10.14, with a high estimate of $14 and a low estimate of $6. The ...

The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 16.03 / share. This is an increase of 8.91% from the prior estimate of 14.72 dated July 5, 2023.

Recursion Pharmaceuticals' stock experienced a 10.06% surge on Monday, indicating strong investor confidence in the company's innovations. The completion of BioHive-2 marks a pivotal moment for ...

As of Wednesday, December 17, Recursion Pharmaceuticals, Inc.’s RXRX share price has surged by 13.10%, which has investors questioning if this is right time to sell.

Fintel reports that on May 9, 2023, Keybanc maintained coverage of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) with a Overweight recommendation. As of April 24, 2023, the average one-year price ...

Bayer and digital biology company Recursion Inc. entered into a strategic collaboration agreement to leverage Recursion’s purpose-built, artificial intelligence-guided drug discovery platform and ...

We recently compiled a list of the Last Week’s Top 10 Stocks Post Double-Digit Gains. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against ...